Naohiko Koshikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Naohiko Koshikawa has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Toru Yoshimura
Research and Development, Abbott Japan LLC, Matsudo 270-2214, Japan
5 shared publications Motoharu Seiki
Division of Cancer Cell Research Institute of Medical Science University of Tokyo Tokyo Japan
4 shared publicationsNobuaki Funahashi
School of Life Science and Technology, Institute of Science Tokyo, Yokohama, Japan
4 shared publicationsRyo Kaneko
Department of Life Science and Technology, Institute of Science Tokyo, Yokohama, Japan
4 shared publications- Shuichi Kaneko
Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
4 shared publications - Taro Yamashita
Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
4 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Proteolytic EphA2 fragments cooperatively promote hepatocellular carcinoma progression
EphA2 is a receptor tyrosine kinase that suppresses tumor growth when bound by its ligand ephrin-A1 (EA1), but promotes tumor progression in the absence of ligand. In hepatocellular carcinoma (HCC) cells, EphA2 is proteolytically cleaved by membrane-type 1 matrix metalloproteinase (MT1-MMP), producing a C-terminal fragment (EphA2-CF) and an N-terminal fragment (EphA2-NF). The functional role of these cleavage fragments on HCC remains unclear. Herein, we investigated their roles in hepatocarcinogenesis and malignant progression. Western blotting and membrane biotinylation assays revealed that EphA2-CF was present in HCC cells co-expressing EphA2 and MT1-MMP. EphA2-CF-expressing cells were resistant to EA1-induced growth suppression, while MT1-MMP knockdown restored EA1 sensitivity. In Hep3B cells, stable EphA2-CF expression confirmed resistance to EA1-mediated inhibition of proliferation and survival. Mechanistically, EphA2-CF sustained oncogenic signaling through constitutive phosphorylation at EphA2-S 897 , while failing to induce Y 588 phosphorylation after EA1 stimulation. Mutation of EphA2-S 897 abolished EphA2-CF-driven proliferation and survival. Reverse-phase protein array identified activation of the EGFR-AKT axis and inactivation of GSK3β as key downstream events. Both pharmacological inhibition of EGFR or AKT, and activation of GSK3β suppressed EphA2-CF-driven proliferation. Furthermore, enforced expression of a constitutively active GSK3β mutant (S9A) markedly suppressed EphA2-CF–driven tumorigenesis in mice, genetically validating GSK3β inactivation as a critical effector of EphA2-CF oncogenic signaling. In addition, soluble EphA2-NF functioned as a decoy receptor for EA1, blocking its tumor-suppressive activity. These findings demonstrate that MT1-MMP–mediated EphA2 processing promotes HCC malignancy via dual mechanisms: EphA2-CF drives ligand-independent EGFR/AKT/GSK3β signaling, while EphA2-NF inhibits EA1-mediated tumor suppression.
- 29 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessProteolytic EphA2 fragments cooperatively promote hepatocellular carcinoma progression
EphA2 is a receptor tyrosine kinase that suppresses tumor growth when bound by its ligand ephrin-A1 (EA1), but promotes tumor progression in the absence of ligand. In hepatocellular carcinoma (HCC) cells, EphA2 is proteolytically cleaved by membrane-type 1 matrix metalloproteinase (MT1-MMP), producing a C-terminal fragment (EphA2-CF) and an N-terminal fragment (EphA2-NF). The functional role of these cleavage fragments on HCC remains unclear. Herein, we investigated their roles in hepatocarcinogenesis and malignant progression. Western blotting and membrane biotinylation assays revealed that EphA2-CF was present in HCC cells co-expressing EphA2 and MT1-MMP. EphA2-CF-expressing cells were resistant to EA1-induced growth suppression, while MT1-MMP knockdown restored EA1 sensitivity. In Hep3B cells, stable EphA2-CF expression confirmed resistance to EA1-mediated inhibition of proliferation and survival. Mechanistically, EphA2-CF sustained oncogenic signaling through constitutive phosphorylation at EphA2-S 897 , while failing to induce Y 588 phosphorylation after EA1 stimulation. Mutation of EphA2-S 897 abolished EphA2-CF-driven proliferation and survival. Reverse-phase protein array identified activation of the EGFR-AKT axis and inactivation of GSK3β as key downstream events. Both pharmacological inhibition of EGFR or AKT, and activation of GSK3β suppressed EphA2-CF-driven proliferation. Furthermore, enforced expression of a constitutively active GSK3β mutant (S9A) markedly suppressed EphA2-CF–driven tumorigenesis in mice, genetically validating GSK3β inactivation as a critical effector of EphA2-CF oncogenic signaling. In addition, soluble EphA2-NF functioned as a decoy receptor for EA1, blocking its tumor-suppressive activity. These findings demonstrate that MT1-MMP–mediated EphA2 processing promotes HCC malignancy via dual mechanisms: EphA2-CF drives ligand-independent EGFR/AKT/GSK3β signaling, while EphA2-NF inhibits EA1-mediated tumor suppression.
- 13 June 2025
- Published by Wiley in European Journal of Organic Chemistry
Facile synthesis of 5-halo-1,2,3-triazole-fused benzotricyclic frameworks from 1-(ω-azidoalkyl)-2-(2,2-dihalovinyl)arenes and their application in fluorescent triazole derivatives
By heating 1‐(ω‐azidoalkyl)‐2‐(2,2‐dihalovinyl)arenes in DMF, intramolecular Huisgen cycloaddition between the azido group and the 1,1‐dihalovinyl moiety proceeded smoothly to afford 5‐halo‐1,2,3‐triazole‐fused tricyclic benzocondensed compounds. Leveraging the remaining halogen groups, carbon‐chain extension via Mizoroki–Heck or Suzuki–Miyaura coupling reactions, followed by an intramolecular Friedel–Crafts reaction, furnished polycyclic systems incorporating fused triazole rings. Furthermore, transformation of the halogen groups into 2‐nitrobenzene derivatives via Suzuki–Miyaura cross‐coupling, followed by a Cadogan reaction using triphenylphosphine, provided a series of fluorescent pentacyclic compounds.
- 13 June 2025
- Published by Wiley in European Journal of Organic Chemistry
Facile synthesis of 5-halo-1,2,3-triazole-fused benzotricyclic frameworks from 1-(ω-azidoalkyl)-2-(2,2-dihalovinyl)arenes and their application in fluorescent triazole derivatives
By heating 1‐(ω‐azidoalkyl)‐2‐(2,2‐dihalovinyl)arenes in DMF, intramolecular Huisgen cycloaddition between the azido group and the 1,1‐dihalovinyl moiety proceeded smoothly to afford 5‐halo‐1,2,3‐triazole‐fused tricyclic benzocondensed compounds. Leveraging the remaining halogen groups, carbon‐chain extension via Mizoroki–Heck or Suzuki–Miyaura coupling reactions, followed by an intramolecular Friedel–Crafts reaction, furnished polycyclic systems incorporating fused triazole rings. Furthermore, transformation of the halogen groups into 2‐nitrobenzene derivatives via Suzuki–Miyaura cross‐coupling, followed by a Cadogan reaction using triphenylphosphine, provided a series of fluorescent pentacyclic compounds.
- Open Access
- 17 April 2025
- Published by Elsevier in The American Journal of Pathology
- Vol. 195 (7) , 1328-1339
Laminin-γ2–NR6A1 Fusion Protein Promotes Metastatic Potential in Non–Small-Cell Lung Carcinoma Cells without Epidermal Growth Factor Receptor Mutation
- 17 April 2025
- Published by Elsevier in The American Journal of Pathology
- Vol. 195 (7) , 1328-1339
Open AccessLaminin-γ2–NR6A1 Fusion Protein Promotes Metastatic Potential in Non–Small-Cell Lung Carcinoma Cells without Epidermal Growth Factor Receptor Mutation
- Open Access
- 14 August 2024
- Published by Elsevier in Experimental Cell Research
- Vol. 442 (2) , 114188
Oncofetal morphogenesis similar to embryonic gut formation by a subpopulation of DLD-1 human colon cancer cells
- 14 August 2024
- Published by Elsevier in Experimental Cell Research
- Vol. 442 (2) , 114188
Open AccessOncofetal morphogenesis similar to embryonic gut formation by a subpopulation of DLD-1 human colon cancer cells
- Open Access
- 1 July 2024
- Published by Wiley in Cancer Science
- Vol. 115 (9) , 2972-2984
Hepatocyte transformation is induced by laminin γ2 monomer
Serum laminin‐γ2 monomer (Lm‐γ2m) is a potent predictive biomarker for hepatocellular carcinoma (HCC) onset in patients with hepatitis C infection who achieve a sustained virologic response with liver cirrhosis (LC) and for the onset of extrahepatic metastases in early‐stage HCC. Although Lm‐γ2m involvement in late‐stage cancer progression has been well investigated, its precise roles in HCC onset remain to be systematically investigated. Therefore, we analyzed an HCC model, human hepatocytes and cholangiocytes, and surgically resected liver tissues from patients with HCC to understand the roles of Lm‐γ2m in HCC onset. Ck‐19‐ and EpCAM‐positive hepatic progenitor cells (HPCs) in the liver of pdgf‐c transgenic HCC mouse model with ductular reaction showed ectopic expression of Lm‐γ2m. Forced expression of Lm‐γ2m in hepatocytes adjacent to HPCs resulted in enhanced tumorigenicity, cell proliferation, and migration in immortalized hepatocytes, but not in cholangiocytes in vitro. Further, pharmacological inhibition of epidermal growth factor receptor (EGFR) and c‐Jun activator JNK suppressed Lm‐γ2m‐induced hepatocyte transformation, suggesting the involvement of EGFR/c‐Jun signaling in the transformation, leading to HCC development. Finally, immunohistochemical staining of HCC tissues revealed a high level of Lm‐γ2 expression in the HPCs of the liver with ductular reaction in normal liver adjacent to HCC tissues. Overall, HPC‐derived Lm‐γ2m in normal liver with ductular reaction acts as a paracrine growth factor on surrounding hepatocytes and promotes their cellular transformation through the EGFR/c‐Jun signaling pathway. Furthermore, this is the first report on Lm‐γ2m expression detected in the normal liver with ductular reaction, a human precancerous lesion of HCC.
- 1 July 2024
- Published by Wiley in Cancer Science
- Vol. 115 (9) , 2972-2984
Open AccessHepatocyte transformation is induced by laminin γ2 monomer
Serum laminin‐γ2 monomer (Lm‐γ2m) is a potent predictive biomarker for hepatocellular carcinoma (HCC) onset in patients with hepatitis C infection who achieve a sustained virologic response with liver cirrhosis (LC) and for the onset of extrahepatic metastases in early‐stage HCC. Although Lm‐γ2m involvement in late‐stage cancer progression has been well investigated, its precise roles in HCC onset remain to be systematically investigated. Therefore, we analyzed an HCC model, human hepatocytes and cholangiocytes, and surgically resected liver tissues from patients with HCC to understand the roles of Lm‐γ2m in HCC onset. Ck‐19‐ and EpCAM‐positive hepatic progenitor cells (HPCs) in the liver of pdgf‐c transgenic HCC mouse model with ductular reaction showed ectopic expression of Lm‐γ2m. Forced expression of Lm‐γ2m in hepatocytes adjacent to HPCs resulted in enhanced tumorigenicity, cell proliferation, and migration in immortalized hepatocytes, but not in cholangiocytes in vitro. Further, pharmacological inhibition of epidermal growth factor receptor (EGFR) and c‐Jun activator JNK suppressed Lm‐γ2m‐induced hepatocyte transformation, suggesting the involvement of EGFR/c‐Jun signaling in the transformation, leading to HCC development. Finally, immunohistochemical staining of HCC tissues revealed a high level of Lm‐γ2 expression in the HPCs of the liver with ductular reaction in normal liver adjacent to HCC tissues. Overall, HPC‐derived Lm‐γ2m in normal liver with ductular reaction acts as a paracrine growth factor on surrounding hepatocytes and promotes their cellular transformation through the EGFR/c‐Jun signaling pathway. Furthermore, this is the first report on Lm‐γ2m expression detected in the normal liver with ductular reaction, a human precancerous lesion of HCC.
- Open Access
- 15 September 2023
- Published by American Association for Cancer Research (AACR)
Data from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
Cleavage of erythropoietin-producing hepatocellular ephrin receptor A2 (EphA2) triggers malignant progression and yields an N-terminal fragment (EphA2-NF) detectable in sera from patients with pancreatic ductal carcinoma. We established a quantitative automated chemiluminescence immunoassay for EphA2-NF and evaluated serum EphA2-NF levels as a biomarker to diagnose pancreatic ductal carcinoma in the test and validation cohorts. The EphA2-NF value was elevated (above the cutoff: mean ± SD) in more than half of the patients with stage I/II pancreatic ductal carcinoma. Among patients receiving standard chemotherapy for pancreatic ductal carcinoma [gemcitabine plus nab-paclitaxel (GnP)], the median survival time of patients with elevated serum EphA2-NF was half that of patients with values below the cutoff. Patients with intraductal papillary mucinous neoplasm (IPMN), a precancerous pancreatic ductal carcinoma lesion, also show high serum EphA2 levels, which are associated with an increase in pancreatic duct size and the development of pancreatic ductal carcinoma in some cases. IHC showed loss of EphA2-NF staining in IPMN with pancreatic ductal carcinoma, but not in the normal epithelium or IPMN without pancreatic ductal carcinoma, regardless of the histologic grade. These results suggest that EphA2 cleavage is an essential event that occurs very early in pancreatic ductal carcinoma development, and that the consequent release of EphA2-NF can be detected in the serum. Thus, serum EphA2-NF could be a diagnostic biomarker for very early-stage pancreatic ductal carcinoma and pancreatic ductal carcinoma development from high-risk IPMN and as a prognostic biomarker after chemotherapy with GnP.Significance:EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.
- 15 September 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
Cleavage of erythropoietin-producing hepatocellular ephrin receptor A2 (EphA2) triggers malignant progression and yields an N-terminal fragment (EphA2-NF) detectable in sera from patients with pancreatic ductal carcinoma. We established a quantitative automated chemiluminescence immunoassay for EphA2-NF and evaluated serum EphA2-NF levels as a biomarker to diagnose pancreatic ductal carcinoma in the test and validation cohorts. The EphA2-NF value was elevated (above the cutoff: mean ± SD) in more than half of the patients with stage I/II pancreatic ductal carcinoma. Among patients receiving standard chemotherapy for pancreatic ductal carcinoma [gemcitabine plus nab-paclitaxel (GnP)], the median survival time of patients with elevated serum EphA2-NF was half that of patients with values below the cutoff. Patients with intraductal papillary mucinous neoplasm (IPMN), a precancerous pancreatic ductal carcinoma lesion, also show high serum EphA2 levels, which are associated with an increase in pancreatic duct size and the development of pancreatic ductal carcinoma in some cases. IHC showed loss of EphA2-NF staining in IPMN with pancreatic ductal carcinoma, but not in the normal epithelium or IPMN without pancreatic ductal carcinoma, regardless of the histologic grade. These results suggest that EphA2 cleavage is an essential event that occurs very early in pancreatic ductal carcinoma development, and that the consequent release of EphA2-NF can be detected in the serum. Thus, serum EphA2-NF could be a diagnostic biomarker for very early-stage pancreatic ductal carcinoma and pancreatic ductal carcinoma development from high-risk IPMN and as a prognostic biomarker after chemotherapy with GnP.Significance:EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.
- Open Access
- 15 September 2023
- Published by American Association for Cancer Research (AACR)
Data from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
Cleavage of erythropoietin-producing hepatocellular ephrin receptor A2 (EphA2) triggers malignant progression and yields an N-terminal fragment (EphA2-NF) detectable in sera from patients with pancreatic ductal carcinoma. We established a quantitative automated chemiluminescence immunoassay for EphA2-NF and evaluated serum EphA2-NF levels as a biomarker to diagnose pancreatic ductal carcinoma in the test and validation cohorts. The EphA2-NF value was elevated (above the cutoff: mean ± SD) in more than half of the patients with stage I/II pancreatic ductal carcinoma. Among patients receiving standard chemotherapy for pancreatic ductal carcinoma [gemcitabine plus nab-paclitaxel (GnP)], the median survival time of patients with elevated serum EphA2-NF was half that of patients with values below the cutoff. Patients with intraductal papillary mucinous neoplasm (IPMN), a precancerous pancreatic ductal carcinoma lesion, also show high serum EphA2 levels, which are associated with an increase in pancreatic duct size and the development of pancreatic ductal carcinoma in some cases. IHC showed loss of EphA2-NF staining in IPMN with pancreatic ductal carcinoma, but not in the normal epithelium or IPMN without pancreatic ductal carcinoma, regardless of the histologic grade. These results suggest that EphA2 cleavage is an essential event that occurs very early in pancreatic ductal carcinoma development, and that the consequent release of EphA2-NF can be detected in the serum. Thus, serum EphA2-NF could be a diagnostic biomarker for very early-stage pancreatic ductal carcinoma and pancreatic ductal carcinoma development from high-risk IPMN and as a prognostic biomarker after chemotherapy with GnP.Significance:EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.
- 15 September 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
Cleavage of erythropoietin-producing hepatocellular ephrin receptor A2 (EphA2) triggers malignant progression and yields an N-terminal fragment (EphA2-NF) detectable in sera from patients with pancreatic ductal carcinoma. We established a quantitative automated chemiluminescence immunoassay for EphA2-NF and evaluated serum EphA2-NF levels as a biomarker to diagnose pancreatic ductal carcinoma in the test and validation cohorts. The EphA2-NF value was elevated (above the cutoff: mean ± SD) in more than half of the patients with stage I/II pancreatic ductal carcinoma. Among patients receiving standard chemotherapy for pancreatic ductal carcinoma [gemcitabine plus nab-paclitaxel (GnP)], the median survival time of patients with elevated serum EphA2-NF was half that of patients with values below the cutoff. Patients with intraductal papillary mucinous neoplasm (IPMN), a precancerous pancreatic ductal carcinoma lesion, also show high serum EphA2 levels, which are associated with an increase in pancreatic duct size and the development of pancreatic ductal carcinoma in some cases. IHC showed loss of EphA2-NF staining in IPMN with pancreatic ductal carcinoma, but not in the normal epithelium or IPMN without pancreatic ductal carcinoma, regardless of the histologic grade. These results suggest that EphA2 cleavage is an essential event that occurs very early in pancreatic ductal carcinoma development, and that the consequent release of EphA2-NF can be detected in the serum. Thus, serum EphA2-NF could be a diagnostic biomarker for very early-stage pancreatic ductal carcinoma and pancreatic ductal carcinoma development from high-risk IPMN and as a prognostic biomarker after chemotherapy with GnP.Significance:EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.
- Open Access
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (9) , 1862-1874
EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
Cleavage of erythropoietin-producing hepatocellular ephrin receptor A2 (EphA2) triggers malignant progression and yields an N-terminal fragment (EphA2-NF) detectable in sera from patients with pancreatic ductal carcinoma. We established a quantitative automated chemiluminescence immunoassay for EphA2-NF and evaluated serum EphA2-NF levels as a biomarker to diagnose pancreatic ductal carcinoma in the test and validation cohorts. The EphA2-NF value was elevated (above the cutoff: mean ± SD) in more than half of the patients with stage I/II pancreatic ductal carcinoma. Among patients receiving standard chemotherapy for pancreatic ductal carcinoma [gemcitabine plus nab-paclitaxel (GnP)], the median survival time of patients with elevated serum EphA2-NF was half that of patients with values below the cutoff. Patients with intraductal papillary mucinous neoplasm (IPMN), a precancerous pancreatic ductal carcinoma lesion, also show high serum EphA2 levels, which are associated with an increase in pancreatic duct size and the development of pancreatic ductal carcinoma in some cases. IHC showed loss of EphA2-NF staining in IPMN with pancreatic ductal carcinoma, but not in the normal epithelium or IPMN without pancreatic ductal carcinoma, regardless of the histologic grade. These results suggest that EphA2 cleavage is an essential event that occurs very early in pancreatic ductal carcinoma development, and that the consequent release of EphA2-NF can be detected in the serum. Thus, serum EphA2-NF could be a diagnostic biomarker for very early-stage pancreatic ductal carcinoma and pancreatic ductal carcinoma development from high-risk IPMN and as a prognostic biomarker after chemotherapy with GnP. Significance: EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (9) , 1862-1874
Open AccessEphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
Cleavage of erythropoietin-producing hepatocellular ephrin receptor A2 (EphA2) triggers malignant progression and yields an N-terminal fragment (EphA2-NF) detectable in sera from patients with pancreatic ductal carcinoma. We established a quantitative automated chemiluminescence immunoassay for EphA2-NF and evaluated serum EphA2-NF levels as a biomarker to diagnose pancreatic ductal carcinoma in the test and validation cohorts. The EphA2-NF value was elevated (above the cutoff: mean ± SD) in more than half of the patients with stage I/II pancreatic ductal carcinoma. Among patients receiving standard chemotherapy for pancreatic ductal carcinoma [gemcitabine plus nab-paclitaxel (GnP)], the median survival time of patients with elevated serum EphA2-NF was half that of patients with values below the cutoff. Patients with intraductal papillary mucinous neoplasm (IPMN), a precancerous pancreatic ductal carcinoma lesion, also show high serum EphA2 levels, which are associated with an increase in pancreatic duct size and the development of pancreatic ductal carcinoma in some cases. IHC showed loss of EphA2-NF staining in IPMN with pancreatic ductal carcinoma, but not in the normal epithelium or IPMN without pancreatic ductal carcinoma, regardless of the histologic grade. These results suggest that EphA2 cleavage is an essential event that occurs very early in pancreatic ductal carcinoma development, and that the consequent release of EphA2-NF can be detected in the serum. Thus, serum EphA2-NF could be a diagnostic biomarker for very early-stage pancreatic ductal carcinoma and pancreatic ductal carcinoma development from high-risk IPMN and as a prognostic biomarker after chemotherapy with GnP. Significance: EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.
- Open Access
- 1 January 2023
- Published by Japanese Electrophoresis Society in Electrophoresis Letters
- Vol. 67 (2) , 59-64
A novel diagnostic and predictive biomarker for the development of liver cancer and extrahepatic metastasis using the serum laminin γ2 monomer
ラミニン(Lm)-γ2鎖は,Lm-α3,Lm-β3鎖と会合し,細胞外マトリックスタンパク質Lm-332を形成し,細胞接着因子として上皮構造を安定的に維持する役割を担う.一方,Lm-γ2鎖は進行がんの浸潤先進部で単鎖(Lm-γ2m)として発現し,EGF受容体の活性化を介してがん化を促進することが知られている.これまでに,Lm-γ2mが肝細胞がんの診断,発がん予測,遠隔転移を予測する血清バイオマーカーになることを見いだしている.さらに,Lm-γ2鎖をコードするLAMC2遺伝子と核内受容体NR6A1遺伝子が染色体転座により融合した融合遺伝子の翻訳産物(Lm-γ2F)を見いだし,がん化の動力源として役割を明らかとした.本総説では,Lm-γ2mとLm-γ2Fが,がん化促進を制御する分子メカニズムと血清バイオマーカーとしての臨床的有用性について紹介する.
- 1 January 2023
- Published by Japanese Electrophoresis Society in Electrophoresis Letters
- Vol. 67 (2) , 59-64
Open AccessA novel diagnostic and predictive biomarker for the development of liver cancer and extrahepatic metastasis using the serum laminin γ2 monomer
ラミニン(Lm)-γ2鎖は,Lm-α3,Lm-β3鎖と会合し,細胞外マトリックスタンパク質Lm-332を形成し,細胞接着因子として上皮構造を安定的に維持する役割を担う.一方,Lm-γ2鎖は進行がんの浸潤先進部で単鎖(Lm-γ2m)として発現し,EGF受容体の活性化を介してがん化を促進することが知られている.これまでに,Lm-γ2mが肝細胞がんの診断,発がん予測,遠隔転移を予測する血清バイオマーカーになることを見いだしている.さらに,Lm-γ2鎖をコードするLAMC2遺伝子と核内受容体NR6A1遺伝子が染色体転座により融合した融合遺伝子の翻訳産物(Lm-γ2F)を見いだし,がん化の動力源として役割を明らかとした.本総説では,Lm-γ2mとLm-γ2Fが,がん化促進を制御する分子メカニズムと血清バイオマーカーとしての臨床的有用性について紹介する.
- Open Access
- 24 November 2022
- Published by Wiley in Cancer Science
- Vol. 114 (2) , 348-356
Proteolytic cleavage of membrane proteins by membrane type‐1 MMP regulates cancer malignant progression
Strategies to develop cancer therapies using inhibitors that target matrix metalloproteinases (MMPs), particularly membrane type-1 MMP (MT1-MMP), have failed. This is predominantly attributed to the specificity of MMP inhibitors and numerous functions of MMPs; therefore, targeting substrates with such broad specificity can lead to off-target effects. Thus, new drug development for cancer therapeutics should focus on the ability of MT1-MMP to break down substrates, such as functional cell membrane proteins, to regulate the functions of these proteins that promote tumor malignancy. In this review, we discuss the mechanism by which proteolysis of cell surface proteins by MT1-MMP promotes progression of malignant tumor cells. In addition, we discuss the two protein fragments generated by limited cleavage of erythropoietin-producing hepatoma receptor tyrosine kinase A2 (EphA2-NF, -CF), which represent a promising basis for developing new cancer therapies and diagnostic techniques.
- 24 November 2022
- Published by Wiley in Cancer Science
- Vol. 114 (2) , 348-356
Open AccessProteolytic cleavage of membrane proteins by membrane type‐1 MMP regulates cancer malignant progression
Strategies to develop cancer therapies using inhibitors that target matrix metalloproteinases (MMPs), particularly membrane type-1 MMP (MT1-MMP), have failed. This is predominantly attributed to the specificity of MMP inhibitors and numerous functions of MMPs; therefore, targeting substrates with such broad specificity can lead to off-target effects. Thus, new drug development for cancer therapeutics should focus on the ability of MT1-MMP to break down substrates, such as functional cell membrane proteins, to regulate the functions of these proteins that promote tumor malignancy. In this review, we discuss the mechanism by which proteolysis of cell surface proteins by MT1-MMP promotes progression of malignant tumor cells. In addition, we discuss the two protein fragments generated by limited cleavage of erythropoietin-producing hepatoma receptor tyrosine kinase A2 (EphA2-NF, -CF), which represent a promising basis for developing new cancer therapies and diagnostic techniques.